CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL TRIAL OF AMMOXETINE HYDROCHLORIDE ENTERIC-COATED TABLETS (HA1406) FOR THE TREATMENT OF PATIENTS WITH DEPRESSION MET THE PRIMARY ENDPOINT

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase III clinical trial (Protocol No.: HA1406–007) of Ammoxetine Hydrochloride Enteric-coated Tablets ("**HA1406**"), a Class 1 innovative drug developed by the Group as a novel, potent selective dual serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor (SNRIs), for the treatment of patients with depression, has successfully met its pre-specified primary efficacy endpoint, with results demonstrating both statistically significant differences and clinically meaningful benefits. HA1406 exhibited favourable efficacy and safety, and is expected to become a first-line treatment for depression.

Depression is a common mental disorder characterised by core clinical features of significant and persistent low mood, diminished interest and anhedonia, and is one of the leading causes of the global disease burden. Although existing antidepressants are widely used in clinical practice, a considerable proportion of patients respond poorly to current treatments. Besides, some drugs have limitations such as delayed onset of action and notable adverse reactions, representing a significant unmet medical need.

HA1406–007 is a multicentre, randomised, double-blind, double-dummy, placebo- and active-controlled, parallel-group Phase III clinical trial designed to evaluate the efficacy and safety of Ammoxetine Hydrochloride Enteric-coated Tablets in the treatment of patients with depression. The results showed that the trial met its primary endpoint, with the change from baseline in the Montgomery — Åsberg Depression Rating Scale (MADRS) score for HA1406 at the end of Week 8 of treatment being significantly superior to that of the placebo ($P < 0.0001$), and numerically superior to the active control. HA1406 demonstrated favourable trends of benefit across multiple secondary endpoints and showed a good safety profile. Detailed data from this study will be presented at a forthcoming international academic conference. HA1406 may offer additional treatment options for patients with depression.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 27 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.